Stephen Michael Kelsey - 16 Sep 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Senior Advisor to the Chief Executive Officer
Issuer ticker: RVMD
Reported as of: 16 Sep 2026
Net transaction value: -$1,109,554
SEC form: 4
Accepted by SEC: 18 Sep 2026, 18:04:03 UTC
Prior SEC filing: 15 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey

Filing notes and source

Key filing fact

Stephen Michael Kelsey filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Sep 2026.

Key facts

This page summarizes Stephen Michael Kelsey's Form 4 filing for Revolution Medicines, Inc. (RVMD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Sep 2026, 18:04.

Change

Previous filing in this sequence was filed on 15 Sep 2026.
Current net transaction value: -$1,109,554.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001462808 Primary reporting owner

Kelsey Stephen Michael

Relationship: Senior Advisor to the Chief Executive Officer
Address: REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: -$16,576
Shares: -85
Change %: -0.03%
Price: $195.01
Shares after: 291,791
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: -$1,092,979
Shares: -5,484
Change %: -1.9%
Price: $199.30
Shares after: 286,307
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Footnote F2

The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 65,613 restricted stock units.

SEC remarks

Senior Advisor to the Chief Executive Officer